Dr. Elyse Watkins, DHSc, PA-C, DFAAPA
Hidradenitis suppurativa (HS) is a chronic debilitating inflammatory skin disease characterized by recurrent painful nodules, abscesses, and sinus tracts that can lead to scarring and can cause significant impairment to an individual’s quality of life. The cause of HS is multifactorial; however, genetics and environment play a crucial role in triggering the development of HS. There is no cure for HS and it is difficult to treat. For years, many oral and topical medications, lasers, and surgery have been used to control HS. Currently, adalimumab, a TNF-a inhibitor, is the only FDA-approved medication for the treatment of HS. Other biologics targeting TNF-a, IL-17, IL-12/23, IL-23, and IL-1 are being investigated as potential alternative treatment options. This paper will examine biologic treatments that are currently approved or are being evaluated for the treatment of hidradenitis suppurativa.
Skae A. Hidradenitis Suppuritiva: Current and Emerging Biologic Treatments. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2022; 4(2).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.